Changes in @entity855 , @entity6297 , and P50 of XXXX blood following transfusion of autologous red cells pretreated with @entity7954 in vitro.

@entity7955 @entity6297 @entity137 @entity7954 @entity235 @entity6298 @entity26 @entity855
Red cells treated with @entity7954 ( @entity7955 ) in vitro were reinfused into the donor @entity235 and were monitored for changes in @entity855 ( @entity855 ), @entity6297 (2,3 DPG), and P50. @entity855 and 2,3 @entity6298 concentrations increased to 116 and 143 percent of control, respectively, when these cells were incubated with 60 mM @entity7955 for 90 minutes at 37 degrees C. The @entity26 dissociation curve shifted to the right, and P50 increased from 24.5 to 30.6 torr as a result of the @entity7955 treatment. When one-half of the circulating red cell volume was treated with @entity7955 and reinfused into the animal, the red cell 2,3 DPG increased to 120 percent of pretransfusion values. The 2,3 DPG level remained elevated during the following day and returned to near pretransfusion levels on the third day. The P50 of the circulating blood paralleled the variations in the red cell 2,3 DPG level, and the capacity for @entity26 delivery was calculated to be raised by 13 to 38 percent for a period of 24 hours. In contrast, elevated red cell @entity855 returned to control values immediately after transfusion. In vivo viability, i.e., 24-hour survival and one-half disappearance time, of the cells pretreated with @entity7955 were determined by a single-isotope technique using 51Cr. The results showed that @entity7955 treatment did not injure the red cells. In addition, there was neither acute @entity137 nor a deleterious hemodynamic effect when large amounts of @entity7955 were administered intravenously. These results suggest that @entity7955 could be used clinically to improve the capacity of the circulating red cells to deliver @entity26 to the tissues.
